[HTML][HTML] Metabolic Syndrome and Atrial Fibrillation: Different Entities or Combined Disorders

GE Zakynthinos, V Tsolaki, E Oikonomou… - Journal of Personalized …, 2023 - mdpi.com
Obesity, hypertension, insulin resistance, and dyslipidemia are all clusters of an entity called
“Metabolic Syndrome”. The global trends of this syndrome's incidence/prevalence continue …

Efficacy and safety of oral anticoagulants in older adult patients with atrial fibrillation: pairwise and network meta-analyses

X Wang, T Wang, X Chen, W Tian, D Ma… - Journal of the American …, 2023 - Elsevier
Objective To evaluate the efficacy and safety of oral anticoagulants for older adult patients
with atrial fibrillation (AF). Design Pairwise and network meta-analyses. Setting and …

[HTML][HTML] Selection of non-vitamin k antagonist oral anticoagulant for stroke prevention in atrial fibrillation based on patient profile: perspectives from Vietnamese …

MT Ton, THQ Ho, VL Nguyen, HM Pham… - European Cardiology …, 2023 - ncbi.nlm.nih.gov
Part 1 of this review provided an overview of AF in Vietnam, with a particular focus on
primary and secondary stroke prevention. Part 2 explores the management of AF in special …

[HTML][HTML] The Synergistic Relationship Between Atrial Fibrillation and Diabetes Mellitus: Implications for Cardiovascular and Metabolic Health

M Mohsin, H Zeyad, H Khalid, A Gapizov, R Bibi… - Cureus, 2023 - ncbi.nlm.nih.gov
Type 2 diabetes mellitus (T2DM) and atrial fibrillation (AF) are widespread chronic
conditions that profoundly impact public health. While the intricate mechanisms linking these …

[HTML][HTML] Место дабигатрана в лечении больных фибрилляцией предсердий в свете современных рекомендаций

ЕС Кропачева, ЕП Панченко - Атеротромбоз, 2023 - cyberleninka.ru
Настоящий обзор посвящен аспектам антикоагулянтной терапии у больных
фибрилляцией предсердий в свете современного представления об этом виде …

[HTML][HTML] АНТИТРОМБОТИЧЕСКАЯ ТЕРАПИЯ ПРИ ФИБРИЛЛЯЦИИ ПРЕДСЕРДИЙ И КОМОРБИДНОЙ ПАТОЛОГИИ-КАК ВЫБРАТЬ ОПТИМАЛЬНОЕ …

ЕВ Шляхто, ЕИ Баранова, ВА Ионин - Российский …, 2021 - cyberleninka.ru
В обзоре обсуждается проблема антикоагулянтной терапии и выбора антикоагулянта
для предупреждения инсульта и системных эмболий у больных с фибрилляцией …

Patients with diabetes mellitus and atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants

F Sbrana, A Ripoli, B Dal Pino - Acta Cardiologica, 2022 - Taylor & Francis
We read with interest Jin et al. titled “A network meta-analysis of non-vitamin K antagonist
oral anticoagulants versus warfarin in patients with atrial fibrillation and diabetes …

Comments on efficacy and safety of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and diabetes mellitus

S Murat, B Murat, B Gorenek - Acta Cardiologica, 2021 - Taylor & Francis
We read with great interest the meta-analysis by Jin et al.[1] comparing the non-vitamin K
antagonist oral anticoagulants (NOACs) and warfarin in terms of efficacy and safety outcome …

[PDF][PDF] Zoznam publikačnej činnosti Doc. MUDr. Samoš, Matej, PhD.

DMUD Samoš - uniba.sk
Ohlasy (7):[o3] 2017 Sen, N.: A 42 year old female lupus anticoagulant positive case with
frequent hospitalization with recurrent stent stenosis. In: International Journal of Scientific …